# A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

> **NCT04242446** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 505 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Bimekizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04242446
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-19
- **Primary completion:** 2022-04-07
- **Final completion:** 2023-02-19
- **Target enrollment:** 505 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04242446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04242446, "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04242446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*